124 related articles for article (PubMed ID: 37150260)
21. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence.
Kruser TJ; Jarrard DF; Graf AK; Hedican SP; Paolone DR; Wegenke JD; Liu G; Geye HM; Ritter MA
Cancer; 2011 Jun; 117(12):2629-36. PubMed ID: 21656740
[TBL] [Abstract][Full Text] [Related]
22. An unrandomized prospective comparison of urinary continence, bowel symptoms and the need for further procedures in patients with and with no adjuvant radiation after radical prostatectomy.
Hofmann T; Gaensheimer S; Buchner A; Rohloff R; Schilling A
BJU Int; 2003 Sep; 92(4):360-4. PubMed ID: 12930419
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 Trial of Everolimus and Radiation Therapy for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy.
Narayan V; Vapiwala N; Mick R; Subramanian P; Christodouleas JP; Bekelman JE; Deville C; Rajendran R; Haas NB
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):355-361. PubMed ID: 27986349
[TBL] [Abstract][Full Text] [Related]
24. Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07).
Vaugier L; Palpacuer C; Rio E; Goineau A; Pasquier D; Buthaud X; De Laroche G; Beckendorf V; Sargos P; Créhange G; Pommier P; Loos G; Hasbini A; Latorzeff I; Silva M; Denis F; Lagrange JL; Campion L; Supiot S
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1061-1067. PubMed ID: 30557672
[TBL] [Abstract][Full Text] [Related]
25. Quality of Life Changes >10 Years After Postoperative Radiation Therapy After Radical Prostatectomy for Prostate Cancer.
Leufgens F; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):382-388. PubMed ID: 31201895
[TBL] [Abstract][Full Text] [Related]
26. Acute Toxicity Profiles of Hypofractionated Adjuvant and Salvage Radiation Therapy After Radical Prostatectomy: Results of a Prospective Study.
Saldi S; Bellavita R; Lancellotta V; Palumbo I; Lupattelli M; Chierchini S; Falcinelli L; Zucchetti C; Bini V; Aristei C
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):105-111. PubMed ID: 30121233
[TBL] [Abstract][Full Text] [Related]
27. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
28. The effects of PSA kinetics on the outcome of hypofractionated salvage radiotherapy for biochemical recurrence of prostate cancer after prostatectomy.
Ishikawa H; Higuchi K; Kaminuma T; Takezawa Y; Saito Y; Etsunaga T; Maruo K; Kawamura H; Kubo N; Nakano T; Kobayashi M
J Radiat Res; 2020 Nov; 61(6):908-919. PubMed ID: 32888035
[TBL] [Abstract][Full Text] [Related]
29. ¹⁸F-choline positron emission tomography/computed tomography-driven high-dose salvage radiation therapy in patients with biochemical progression after radical prostatectomy: feasibility study in 60 patients.
D'Angelillo RM; Sciuto R; Ramella S; Papalia R; Jereczek-Fossa BA; Trodella LE; Fiore M; Gallucci M; Maini CL; Trodella L
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):296-302. PubMed ID: 25084612
[TBL] [Abstract][Full Text] [Related]
30. Radiotherapy after prostatectomy: is the evidence for dose escalation out there?
King CR; Kapp DS
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):346-50. PubMed ID: 18234451
[TBL] [Abstract][Full Text] [Related]
31. Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer.
Alongi F; Cozzi L; Fogliata A; Iftode C; Comito T; Clivio A; Villa E; Lobefalo F; Navarria P; Reggiori G; Mancosu P; Clerici E; Tomatis S; Taverna G; Graziotti P; Scorsetti M
Anticancer Res; 2013 Oct; 33(10):4537-43. PubMed ID: 24123027
[TBL] [Abstract][Full Text] [Related]
32. First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy.
Valicenti RK; Pugh SL; Trabulsi EJ; Sartor O; Ko EC; Girvigian MR; Rosenthal SA; Shaves ME; Hoffman-Censits JH; Schallenkamp J; Sandler HM
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):695-701. PubMed ID: 29413282
[TBL] [Abstract][Full Text] [Related]
33. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer.
Parikh NR; Kishan AU; Kane N; Diaz-Perez S; Ganapathy E; Nazarian R; Felix C; Mathis C; Bradley M; Sachdeva A; Wyatt B; Basehart V; Zomorodian N; Lin L; King CR; Kupelian PA; Rettig MB; Steinberg ML; Cao M; Knudsen BS; Elashoff D; Schaue D; Reiter RE; Nickols NG
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):930-935. PubMed ID: 32562839
[TBL] [Abstract][Full Text] [Related]
35. Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy.
Deville C; Jain A; Hwang WT; Woodhouse KD; Both S; Wang S; Gabriel PE; Christodouleas JP; Bekelman J; Tochner Z; Vapiwala N
Acta Oncol; 2018 Nov; 57(11):1506-1514. PubMed ID: 30028227
[TBL] [Abstract][Full Text] [Related]
36. Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy.
Ballas LK; Luo C; Chung E; Kishan AU; Shuryak I; Quinn DI; Dorff T; Jhimlee S; Chiu R; Abreu A; Jennelle R; Aron M; Groshen S
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):50-60. PubMed ID: 30605751
[TBL] [Abstract][Full Text] [Related]
37. Hypofractionation for clinically localized prostate cancer.
Hickey BE; James ML; Daly T; Soh FY; Jeffery M
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
[TBL] [Abstract][Full Text] [Related]
38. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
39. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy.
Jereczek-Fossa BA; Zerini D; Vavassori A; Fodor C; Santoro L; Minissale A; Cambria R; Cattani F; Garibaldi C; Serafini F; Matei VD; de Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2009 May; 74(1):115-25. PubMed ID: 19004572
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
Sargos P; Chabaud S; Latorzeff I; Magné N; Benyoucef A; Supiot S; Pasquier D; Abdiche MS; Gilliot O; Graff-Cailleaud P; Silva M; Bergerot P; Baumann P; Belkacemi Y; Azria D; Brihoum M; Soulié M; Richaud P
Lancet Oncol; 2020 Oct; 21(10):1341-1352. PubMed ID: 33002438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
